BIRC5 and prostate cancer: It offers a chance to overcome resistance by incorporating survivin inhibitors into combination chemotherapy, such as prostate cancer cells can be effectively treated with 7F1 and docetaxel combined with survivin dimerization inhibitors to overcome docetaxel resistance [26].